Integrin α1 subunit is up-regulated in colorectal cancer

Abstract

BackgroundColorectal cancer remains one of the leading causes of death from cancer in industrialized countries. Integrins are a family of heterodimeric glycoproteins involved in bidirectional cell signaling and participate in the regulation of cell shape, adhesion, migration, differentiation, gene transcription, survival and proliferation. The α1 subunit is known to be involved in RAS/ERK proliferative pathway activation and plays an important role in mammary carcinoma cell proliferation and migration. In the small intestine, α1 is present in the crypt proliferative compartment and absent in the villus, but nothing is known about its expression in the colon mucosa, or in colorectal cancer.ResultsIn the present study, we demonstrated that in the colon mucosa, α1 is present in the basolateral domain of the proliferative cells of the crypt, and in the surrounding myofibroblasts. We found higher levels of α1 mRNA in 86% of tumours compared to their corresponding matched margin tissues. Immunohistochemical analysis showed that α1 staining was moderate to high in 65% of tumour cells and 97% of the reactive cells surrounding the tumour cells vs 23% of normal epithelial cells.ConclusionOur findings suggest an active role for the α1β1 integrin in colorectal cancer progression.

APE1/Ref‐1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single‐cellRNAsequencing

“…6D). COMMD7 (You et al ., 2017), ITGA1 (Boudjadi et al ., 2013; Gulubova, 2004; Schadendorf et al ., 1996), RAB3D (Luo et al ., 2016; Yang et al ., 2003), and TNFAIP2 (Chen et al ., 2011; Jia et al ., 2016) have all been shown to be upregulated in various cancers including PDAC. While we cannot assume these changes will be universal in all PDAC samples, this consistency suggests that some of these genes could make promising targets or biomarkers for APE1‐based therapy or combination therapies that potentially will be useful across multiple PDAC tumor subtypes and in other tumor types.…”

Derivate Isocorydine (d-ICD) Suppresses Migration and Invasion of Hepatocellular Carcinoma Cell by Downregulating ITGA1 Expression

“…Further studies have suggested that integrin alpha1 is closely associated with angiogenesis [13,14]. Recent studies have revealed that ITGA1 is upregulated in higher metastasis potential melanoma cells, gastric cancer cells, and colorectal cancer cells [15,16,17]. Blocking integrin α1 with a therapeutic monoclonal antibody or knocking out ITGA1 in mice both indicated that ITGA1 promoted tumor cell migration and invasion [18,19,20].…”

ITGA1 (integrin, alpha 1)

“…As reported previously, α1 is present in fibroblasts, endothelial cells and smooth muscle cells (Gardner, 2014). In the gut, α1 is expressed in myofibroblast cells surrounding the crypts of the colon and small intestinal mucosa (Boudjadi et al, 2013). α1 is present in epithelial cells of the endometrium, kidney and intestine.…”

“…Expression is found to be higher in epithelial cells and the surrounding reactive cells (Boudjadi et al, 2013). Also, α1β1 is present in the early stages of colorectal cancer which could constitute a useful early diagnostic marker.…”

“…α1 is present in epithelial cells of the endometrium, kidney and intestine. In the latter, α1 is present only in proliferating crypt cells while its exclusive partner β1 is constitutively expressed in all intestinal cells (Beaulieu, 1992;Boudjadi et al, 2013). In these cells, α1 is observed in the basolateral portion of the cytoplasmic membrane (figure 3).…”